Name | Number of supported studies | Average coverage | |
---|---|---|---|
hepatocyte | 5 studies | 30% ± 14% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
liver | 3 studies | 29% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 7837.48 | 226 / 226 | 100% | 123.99 | 404 / 406 |
prostate | 100% | 1649.60 | 244 / 245 | 100% | 95.54 | 500 / 502 |
intestine | 100% | 1546.07 | 966 / 966 | 95% | 34.58 | 500 / 527 |
stomach | 100% | 2574.08 | 359 / 359 | 93% | 32.31 | 266 / 286 |
pancreas | 100% | 13084.30 | 328 / 328 | 92% | 22.57 | 164 / 178 |
skin | 100% | 1506.86 | 1808 / 1809 | 79% | 15.18 | 371 / 472 |
breast | 100% | 1450.77 | 458 / 459 | 74% | 15.42 | 831 / 1118 |
lung | 99% | 1297.44 | 571 / 578 | 61% | 11.18 | 699 / 1155 |
bladder | 100% | 1997.52 | 21 / 21 | 52% | 11.85 | 263 / 504 |
esophagus | 93% | 1331.49 | 1339 / 1445 | 54% | 17.70 | 98 / 183 |
thymus | 100% | 1720.81 | 652 / 653 | 45% | 7.73 | 275 / 605 |
uterus | 99% | 1945.81 | 169 / 170 | 32% | 7.29 | 149 / 459 |
adrenal gland | 99% | 1255.21 | 256 / 258 | 30% | 5.57 | 69 / 230 |
ovary | 100% | 2482.91 | 180 / 180 | 20% | 2.56 | 84 / 430 |
kidney | 97% | 704.58 | 86 / 89 | 20% | 4.07 | 178 / 901 |
spleen | 100% | 1051.66 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 100% | 1722.22 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 1080.88 | 1325 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 1206.86 | 793 / 803 | 0% | 0 | 0 / 0 |
heart | 95% | 650.12 | 817 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 93% | 17.08 | 74 / 80 |
lymph node | 0% | 0 | 0 / 0 | 90% | 26.05 | 26 / 29 |
peripheral blood | 83% | 667.84 | 768 / 929 | 0% | 0 | 0 / 0 |
brain | 36% | 128.63 | 962 / 2642 | 25% | 2.87 | 179 / 705 |
tonsil | 0% | 0 | 0 / 0 | 7% | 3.17 | 3 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_1903785 | Biological process | L-valine transmembrane transport |
GO_0006865 | Biological process | amino acid transport |
GO_0015804 | Biological process | neutral amino acid transport |
GO_1905533 | Biological process | negative regulation of L-leucine import across plasma membrane |
GO_0051956 | Biological process | negative regulation of amino acid transport |
GO_0015818 | Biological process | isoleucine transport |
GO_0015820 | Biological process | L-leucine transport |
GO_0016324 | Cellular component | apical plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0098846 | Cellular component | podocyte foot |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0015175 | Molecular function | neutral L-amino acid transmembrane transporter activity |
GO_0015171 | Molecular function | amino acid transmembrane transporter activity |
GO_0015188 | Molecular function | L-isoleucine transmembrane transporter activity |
GO_0015179 | Molecular function | L-amino acid transmembrane transporter activity |
GO_0015190 | Molecular function | L-leucine transmembrane transporter activity |
GO_0005515 | Molecular function | protein binding |
GO_0005304 | Molecular function | L-valine transmembrane transporter activity |
Gene name | SLC43A1 |
Protein name | Solute carrier family 43 member 1 Large neutral amino acids transporter small subunit 3 (L-type amino acid transporter 3) (Prostate cancer overexpressed gene 1 protein) (Solute carrier family 43 member 1) |
Synonyms | LAT3 POV1 PB39 |
Description | FUNCTION: Uniport that mediates the transport of neutral amino acids such as L-leucine, L-isoleucine, L-valine, and L-phenylalanine . The transport activity is sodium ions-independent, electroneutral and mediated by a facilitated diffusion . . |
Accessions | ENST00000530159.5 ENST00000533066.5 E9PJT8 H0YEH0 ENST00000533263.1 E9PR87 ENST00000524995.5 ENST00000534105.5 ENST00000525764.5 E9PJ68 O75387 ENST00000528450.5 [O75387-1] E9PRF0 ENST00000278426.8 [O75387-1] |